Denali Therapeutics Inc.
NEWS
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Today, Noubar Afeyan, founder of Flagship Pioneering, published the platform development company’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
JOBS
IN THE PRESS